Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX4161 for hereditary angioedema prophylaxis
NCT02303626Phase 3Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Dec 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of avoralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc.. Started Dec 2014; status: completed.
02
Drugs
avoralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT02303626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303626.